Gepotidacin Mesylate Patent Expiration

Gepotidacin Mesylate was first introduced by Glaxosmithkline Llc in its drug Blujepa on Mar 25, 2025.


Gepotidacin Mesylate Patents

Given below is the list of patents protecting Gepotidacin Mesylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Blujepa US8389524 Tricyclic nitrogen containing compounds as antibacterial agents Feb 12, 2029 Glaxosmithkline



Gepotidacin Mesylate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List